Tysabri decision will wait until second half of 2005

Share this article:
Biogen Idec and Elan do not expect to issue a decision on the fate of their jointly-marketed multiple sclerosis (MS) drug Tysabri until the second half of 2005, a spokesman for the companies told MM&M.
"We are in the midst of an ongoing process to weigh the risk/benefit ratio of Tysabri. We don't expect that to be complete until the second half of the year," said Jose Juves, a Biogen Idec spokesman. "We will have to wait, at least until then, to form a basis for any decision."
Late last month, both companies announced the discovery of a third case of the rare brain disease, multifocal leukoencephalopathy (ML), in a patient taking Tysabri in a clinical trial. Tysabri was voluntarily withdrawn from the market in February after the companies learned of the ML related deaths of two other patients in clinical trials who took Tysabri in combination with an older Biogen Idec MS drug, Avonex.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.